The murine complement regulator Crry: New insights into the immunobiology of complement regulation

Cellular and Molecular Life Sciences

Volumn 59, Issue 2, 2002, Pages 220-229

  Molina, H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C3; Complement; Complement regulators; Gene targeted mice; Inflammation; Transgenic mice

Indexed keywords

COMPLEMENT;

AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; IMMUNE SYSTEM; IMMUNOBIOLOGY; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; TISSUE INJURY;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; RECEPTORS, COMPLEMENT; T-LYMPHOCYTES;

MURINAE; MUS MUSCULUS; VERTEBRATA;

EID: 0036176966     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8418-6     Document Type: Review

References (67)

1. Complement: A critical test of its biological importance
2. Effector mechanisms of humoral immunity
3. Control of the complement system
4. The regulators of complement activation (RCA) gene cluster
5. Decay-accelerating factor and membrane cofactor protein
6. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP,CD46)
7. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55)
8. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion
9. Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury
10. Deficiecy of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria
11. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria
12. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor
13. Expression of decay-accelerating factor is reduced on hyperplastic synovial lining cells in rheumatoid synovitis
14. Localization of decay accelerating factor in normal and diseased kidneys
15. H deficiency in two brothers with atypical dense intramembranous deposit disease
16. Hereditary porcine membranoproliferative glomerulonephritistype II is caused by factor H deficiency
17. Familial hemolytic-uremic syndrome and homozygous factor H deficiency
18. Complement factor H mutation associated with autosomal recessive atypical hemolytic syndrome
19. Factor H and disease: A complement regulator affects vital body functions
20. Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases
21. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus
22. C3b receptor (CR1) expression on the polymorphonuclear leucocytes from patients with systemic lupus erythematosus
23. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase
24. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes
25. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting
26. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): Preferential expression in testicular germ cells
27. The evolution of mouse and human complement C3-binding proteins: Divergence of form but conservation of function
28. P65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor
29. Expansion of the complement receptor gene family. Identification in the mouse of two new genes related to CR1 and CR2 gene family
30. The murine complement receptor gene family I. Analysis of mCRY gene products and their homology to human CR1
31. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1
32. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein
33. Mouse Crry/p65: Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF
34. Complement inhibitor of rat cell membrane resembling mouse Crry/p65
35. Molecular characterization of rat Crry: Widespread distribution of two alternative forms of Crry mRNA
36. Complement regulation in rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells
37. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement
38. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats
39. The alternative pathway
40. Inhibition of complement regulation is key to the pathogenesis of Heymann nephritis
41. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor
42. Transgenice mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury
43. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis
44. A critical role for murine complement regulator Crry in fetomaternal tolerance
45. Complement and pregnancy: New insights into the immunobiology of the fetomaternal relationship
46. Complement in human reproduction: Activation and control
47. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy
48. The normal fetomaternal immune relationship
49. Immune aspects of pathology of the placental bed contributing to pregnancy pathology
50. A monoclonal antibody to the rat Crry/p65 antigen, a complement regulatory membrane protein, stimulates adhesion and proliferation of thymocytes
51. Crry/p65, a membrane complement regulatory protein, has costimulatory properties om mouse T cells
52. Tissue distribution of the rat analogue of decay-accelerating factor
53. Therapeutic inhibition of the complement system
54. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
55. Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive Arthus reaction in rats
56. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat
57. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis
58. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis
59. Inflammation of the brain in Alzheimer's disease: Implications for therapy
60. Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease
61. Amelioration of lupus-like autoimmune disease in NZB/W F1 mice after treatment with a blocking monoclonal antibody specific for complement component C5
62. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
63. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle
64. Immunology of reproduction: Protecting the placenta
65. Embryos attacked by mom's natural defenses
66. Role of complement regulatory membrane proteins in ischemia-reperfusion injury of rat gastric mucosa
67. Inhibition of a membrane complement regulatory protein by a monoclonal antibody induces acute lethal schock in rats primed with lipopolysaccharide